乳腺浸润性导管癌组织Bmi-1的表达及其临床意义

Expression and clinicopathological relevance of Bmi-1 in invasive mammary ductal cancer

目的:探讨Bmi-1在乳腺浸润性导管癌组织中的表达及其与临床病理特征的关系。方法:免疫组化法检测84例乳腺癌组织中雌激素受体(ER)、孕激素受体(PR)、c-erbB-2和B细胞特异性莫洛尼小鼠白血病病毒整合位点-1(Bmi-1)表达,并取其中43例(51.2%)乳腺癌新鲜肿瘤组织和癌旁的正常组织,采用RT-PCR方法检测其Bmi-1表达。结果:84例乳腺浸润性导管癌组织中Bmi-1蛋白阳性表达率为56.0%(47/84)。43例乳腺癌新鲜肿瘤组织中Bmi-1mRNA阳性表达率为67.4%(29/43)。Bmi-1过表达与临床晚期及ER阴性表达显著相关,P<0.05。Bmi-1表达与患者年龄、肿瘤大小、组织学分级以及PR、c-erbB-2表达均无明显相关性,P>0.05。Bmi-1在乳腺浸润性导管癌与癌旁正常组织中的表达差异有统计学意义,P<0.01。结论:Bmi-1过表达与乳腺浸润性导管癌的发生、发展有关。Bmi-1可能成为预测乳腺浸润性导管癌临床分期的新分子标志。

OBJECTIVE：To investigate the relationship between the expression of Bmi-1 and clinicopathological characteristics in invasive mammary ductal cancer.METHODS： Immunohistochemistry was used to detect the expression of ER,PR,c-erbB-2 and Bmi-1 oncoproteins in 84 cases of invasive mammary ductal carcinoma.RT-PCR assay was used to detect the mRNA expression level of Bmi-1 in 43 cases（51.2% from the 84 cases） of breast cancer and paraneoplastic tissues.RESULTS： The positive rate of Bmi-1 oncoprotein expression was 56.0%（47/84） in 84 cases of mammary carcinoma.The positive rate of Bmi-1 mRNA expression was 67.4%（29/43） for the 43 cases of fresh breast cancer tissue samples.The overexpression of Bmi-1 was positively correlated with clinical advanced stage and negative ER status（P0.05）,but not with age,tumor size,histological grading,and PR,c-erbB-2（P0.05）.Significant different expression of Bmi-1 were found between breast cancer and in paraneoplastic tissues（P0.01）.CONCLUSIONS： The intensive expression of Bmi-1 is related to the development and progression of invasive mammary ductal carcinoma.Bmi-1 may serve as a new molecular marker of clinical staging for invasive mammary ductal carcinoma.